weight loss injections glp-1 Skyrocketing Popularity Puts Agonists for on Cardiology's Radar GLP1 Drug Use For Weight

Pharmacologically this yields a highly selective GHS-R1a agonist which, in classical rodent studies (Raun et al., Eur J Endocrinol 1998), does not significantly elevate cortisolemia, ACTH, prolactin or FSH/LH at effective doses, unlike GHRP-2 and GHRP-6

As drug makers relentlessly lobby for a blank check to keep overcharging Americans, continued bipartisan action to lower drug prices is critical including common sense reforms to stop drugmakers abuse of the patent system, restore competition, and move toward pricing based on clinical value and not on the lavish tax-deductible marketing campaigns brand drug makers use to drive up consumer demand for high-priced drugs and raise costs for everyone, an AHIP spokesperson said in a statement shared with Healthline.

Klarl BA, Lang PA, Kempe DS, Niemoeller OM, Akel A, Sobiesiak M, et al

Topline results announced in December 2025 were positive, showing that orforglipron maintained weight loss after the switch